{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:56:19Z","timestamp":1780498579518,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clinthera.2014.06.014","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T02:17:07Z","timestamp":1406081827000},"page":"1231-1241.e3","source":"Crossref","is-referenced-by-count":20,"title":["Cost of Biologics per Treated Patient across Immune-mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"36","author":[{"given":"Ning","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Chi (Daisy)","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.06.014_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clinthera.2014.06.014_bib2","unstructured":"Enbrel (etanercept) [prescribing information]. lmmunex Corporation, Thousand Oaks, CA."},{"key":"10.1016\/j.clinthera.2014.06.014_bib3","unstructured":"Orencia (abatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb."},{"key":"10.1016\/j.clinthera.2014.06.014_bib4","unstructured":"Humira (adalimumab) [prescribing information]. Abbott Park, Ill: Abbott Laboratories."},{"key":"10.1016\/j.clinthera.2014.06.014_bib5","unstructured":"Cimzia (certolizumab) [prescribing information]. Smyrna, Ga: UCB Inc."},{"key":"10.1016\/j.clinthera.2014.06.014_bib6","unstructured":"Simponi (golimumab) [prescribing information]. Horsham, Pa: Janssen Biotech Inc."},{"key":"10.1016\/j.clinthera.2014.06.014_bib7","unstructured":"Remicade (infliximab) [prescribing information]. Malvern, Pa: Centocor Inc."},{"key":"10.1016\/j.clinthera.2014.06.014_bib8","unstructured":"Rituxan (rituximab) [prescribing information]. South San Francisco, Calif: Genentech Inc."},{"key":"10.1016\/j.clinthera.2014.06.014_bib9","unstructured":"Stelara (ustekinumab) [prescribing information]. Horsham, Pa: Janssen Biotech Inc."},{"key":"10.1016\/j.clinthera.2014.06.014_bib10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2146\/ajhp090487","article-title":"Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis","volume":"67","author":"Harrison","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2014.06.014_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1185\/03007995.2010.483127","article-title":"Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice","volume":"26","author":"Huang","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.06.014_bib12","series-title":"Drug therapy for rheumatoid arthritis in adults: an update. Comparative effectiveness review no. 55. Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I","author":"Donahue","year":"2012"},{"key":"10.1016\/j.clinthera.2014.06.014_bib13","series-title":"Drug therapy for psoriatic arthritis in adults: update of a 2007 report. Comparative effectiveness review no. 54. Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I","author":"Donahue","year":"2007"},{"key":"10.1016\/j.clinthera.2014.06.014_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3111\/13696998.2011.644645","article-title":"Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States","volume":"15","author":"Schabert","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2014.06.014_bib15","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3111\/13696998.2013.820192","article-title":"Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"16","author":"Bonafede","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2014.06.014_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.clinthera.2009.04.002","article-title":"Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population","volume":"31","author":"Ollendorf","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.014_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0149-2918(05)00090-1","article-title":"Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis","volume":"27","author":"Weycker","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.014_bib18","unstructured":"Pharmacy Benefit Managers. Prescription policy choices. http:\/\/www.policychoices.org\/pharmacy_benefit_managers.shtml. Accessed April 9, 2013."},{"key":"10.1016\/j.clinthera.2014.06.014_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1331\/JAPhA.2011.09115","article-title":"Economic impact of pharmacist-reimbursed drug therapy modification","volume":"51","author":"Look","year":"2011","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.clinthera.2014.06.014_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2474-5-36","article-title":"Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study","volume":"5","author":"Gilbert","year":"2004","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2014.06.014_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3111\/13696998.2011.649325","article-title":"Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients","volume":"15","author":"Carter","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2014.06.014_bib22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1185\/030079907X210615","article-title":"Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data","volume":"23","author":"Wu","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.06.014_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12325-012-0007-y","article-title":"Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2014.06.014_bib24","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1345\/aph.1K253","article-title":"Impact of patient and plan design factors on switching to preferred statin therapy","volume":"41","author":"Cox","year":"2007","journal-title":"Ann Pharmacother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T07:55:08Z","timestamp":1538380508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814003774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0149291814003774"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}